So I guess I wasn’t too far off in my previous post about the Pfizer/Novo Nordisk battle for Metsera; in fact, the case I mentioned was cited in Pfizer’s papers (though of course, Metsera disputes its relevance).
Here’s the thing: the legal ability of Metsera to terminate its deal with Pfizer, and enter into a new agreement, entirely depends on the application of the antitrust laws. Novo’s bid is unquestionably higher; the only difficulty is completion risk, given that it presents greater antitrust hurdles than Pfizer’s bid.
So, in one version of the story, there is no chance that regulators would approve the deal with Novo; therefore, it cannot constitute a superior offer. Moreover, Novo’s proposal to pay Metsera cash up front, skipping antitrust review, is itself a violation of the antitrust laws, and so Metsera cannot claim superiority solely due to that feature.
In another version of the story – the version that Metsera tells in its briefing to the Delaware Court of Chancery – Metsera was initially concerned about antitrust risk, which is why it accepted Pfizer’s bid over Novo’s higher one, but Novo has since been consulting with regulators and now is more confident there is
